Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -389K | 0 | 0 | 0 |
| Operating Income | -27M | -42M | -29M | -35M | -27M |
| EBITDA | -26M | -40M | -28M | -33M | -27M |
| Net Income | -26M | -42M | -29M | -36M | -28M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.23
-1.60% today
1Y Change
-81.46%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tempest Therapeutics, Inc. (TPST) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $1.23 and down 81.5% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -322.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -322.0%, free cash flow +19.8% with operating margin 0.0% and ROIC -179.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TPST price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TPST
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TPST Max Drawdown
-89.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TPST and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$28.3M
+20.7% YoY
Free Cash Flow
-$26.1M
+17.5% YoY
Revenue Growth
+0.0%
EPS Growth
-322.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -389K | 0 | 0 | 0 |
| Operating Income | -27M | -42M | -29M | -35M | -27M |
| EBITDA | -26M | -40M | -28M | -33M | -27M |
| Net Income | -26M | -42M | -29M | -36M | -28M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8M | 30M | 39M | 31M | 52M |
| Total Assets | 17M | 41M | 52M | 46M | 73M |
| Total Liabilities | 10M | 22M | 25M | 28M | 37M |
| Shareholder Equity | 7M | 19M | 27M | 18M | 36M |
| Total Debt | 8M | 15M | 21M | 22M | 19M |
| Net Debt | 434K | -15M | -19M | -9M | -33M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
26M
+16.5% YoY
Capital Expenditures
135K
+76.0% YoY
Free Cash Flow
26M
+17.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-309.6%
Debt / Equity
1.22x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.